NCT04776018: Phase 1/2: A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In RRMM

NCT04776018: Phase 1/2: A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

TAK-981 is being tested in combination with anti-CD38 monoclonal antibodies (mAbs) to treat participants who have relapsed or refractory multiple myeloma (RRMM).

The main aims of the study are to evaluate the safety and efficacy of TAK-981 in combination with anti-CD38 (mAbs) and to determine the recommended Phase 2 dose (RP2D).

Participants will be on this combination treatment for 28-day cycles. They will continue with this treatment until disease progression or unacceptable toxicity.

Sponsor

Takeda

Multiple locations

---

ClinicalTrials.gov Identifier: NCT04776018

Official Title: A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combination With Monoclonal Antibodies in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

First Posted : March 1, 2021

Click here to see details on ClinicalTrials.gov

TAK-981-1503

---

Drug: TAK-981

Drug: Mezagitamab

Drug: Daratumumab and Hyaluronidase-fihj

---

TAK 981

Subasumstat (Code C156270)

Subasumstat

SUBASUMSTAT

TAK 981

TAK-981

TAK981

TAK 079

Mezagitamab (Code C148078)

Anti-CD38 MAb TAK-079

Mezagitamab

MEZAGITAMAB

TAK 079

TAK-079

TAK079

---

Locations

United States, Arizona

United States, Florida

United States, Georgia

United States, Indiana

United States, Maryland

United States, Minnesota

United States, Nebraska

United States, New York

United States, Ohio

United States, Texas

United States, Wisconsin